Tweet
Int J Infect Dis. Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - possible lessons from a systematic review of SARS-CoV therapy.
[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]
Int J Infect Dis. 2013 Aug 28. pii: S1201-9712(13)00229-4. doi: 10.1016/j.ijid.2013.07.002. [Epub ahead of print]
Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - possible lessons from a systematic review of SARS-CoV therapy.
Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA.
Source: Pharmacy Services Division, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia.
Abstract
The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections.
Copyright ? 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
KEYWORDS: Interferon, MERS-CoV, Ribavarin, SARS
PMID: 23993766 [PubMed - as supplied by publisher]
-
--------
Int J Infect Dis. 2013 Aug 28. pii: S1201-9712(13)00229-4. doi: 10.1016/j.ijid.2013.07.002. [Epub ahead of print]
Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - possible lessons from a systematic review of SARS-CoV therapy.
Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA.
Source: Pharmacy Services Division, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia.
Abstract
The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections.
Copyright ? 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
KEYWORDS: Interferon, MERS-CoV, Ribavarin, SARS
PMID: 23993766 [PubMed - as supplied by publisher]
-
--------